SK65998A3 - Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product - Google Patents

Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product Download PDF

Info

Publication number: SK65998A3
Authority: SK; Slovakia
Prior art keywords: gdnf; factor; protein product; cells; photoreceptor
Prior art date: 1995-11-29

Application number

SK659-98A

Other languages

English (en)

Slovak (sk)

Inventor

Jean-Claude Marcel Louis

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-29

Filing date

1996-11-22

Publication date

1999-09-10

1996-11-22 Application filed by Amgen Inc filed Critical Amgen Inc

1999-09-10 Publication of SK65998A3 publication Critical patent/SK65998A3/sk

Links

102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 title claims abstract description 182
108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 title claims abstract description 182
108091008695 photoreceptors Proteins 0.000 title claims abstract description 137
238000000034 method Methods 0.000 title claims abstract description 69
108090000623 proteins and genes Proteins 0.000 title claims description 117
102000004169 proteins and genes Human genes 0.000 title claims description 102
101150082979 gdnf gene Proteins 0.000 title 1
230000007850 degeneration Effects 0.000 claims abstract description 33
230000002207 retinal effect Effects 0.000 claims abstract description 30
230000006378 damage Effects 0.000 claims abstract description 21
206010038923 Retinopathy Diseases 0.000 claims abstract description 16
208000017442 Retinal disease Diseases 0.000 claims abstract description 14
208000027418 Wounds and injury Diseases 0.000 claims abstract description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
208000014674 injury Diseases 0.000 claims abstract description 12
201000010099 disease Diseases 0.000 claims abstract description 11
208000002780 macular degeneration Diseases 0.000 claims abstract description 7
206010064930 age-related macular degeneration Diseases 0.000 claims abstract description 5
206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 3
230000000302 ischemic effect Effects 0.000 claims abstract description 3
230000002093 peripheral effect Effects 0.000 claims abstract description 3
238000001356 surgical procedure Methods 0.000 claims abstract description 3
230000003612 virological effect Effects 0.000 claims abstract 2
210000004027 cell Anatomy 0.000 claims description 105
230000004083 survival effect Effects 0.000 claims description 42
238000002360 preparation method Methods 0.000 claims description 36
239000003814 drug Substances 0.000 claims description 32
239000000203 mixture Substances 0.000 claims description 27
108010025020 Nerve Growth Factor Proteins 0.000 claims description 24
210000000608 photoreceptor cell Anatomy 0.000 claims description 24
102000007072 Nerve Growth Factors Human genes 0.000 claims description 23
125000003275 alpha amino acid group Chemical group 0.000 claims description 22
239000003900 neurotrophic factor Substances 0.000 claims description 20
238000002347 injection Methods 0.000 claims description 19
239000007924 injection Substances 0.000 claims description 19
210000004498 neuroglial cell Anatomy 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 14
229920003169 water-soluble polymer Polymers 0.000 claims description 14
238000002513 implantation Methods 0.000 claims description 8
229940124597 therapeutic agent Drugs 0.000 claims description 7
108090000099 Neurotrophin-4 Proteins 0.000 claims description 6
108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 5
102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 5
102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 5
230000001886 ciliary effect Effects 0.000 claims description 5
239000007943 implant Substances 0.000 claims description 5
230000035800 maturation Effects 0.000 claims description 5
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
108090000742 Neurotrophin 3 Proteins 0.000 claims description 4
102000004230 Neurotrophin 3 Human genes 0.000 claims description 4
102100033857 Neurotrophin-4 Human genes 0.000 claims description 4
230000002378 acidificating effect Effects 0.000 claims description 4
229940032018 neurotrophin 3 Drugs 0.000 claims description 4
208000033810 Choroidal dystrophy Diseases 0.000 claims description 3
102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 3
108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 3
102000003967 Fibroblast growth factor 5 Human genes 0.000 claims description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 3
102000003683 Neurotrophin-4 Human genes 0.000 claims description 3
229940025084 amphetamine Drugs 0.000 claims description 3
229940097998 neurotrophin 4 Drugs 0.000 claims description 3
230000001105 regulatory effect Effects 0.000 claims description 3
201000001321 Bardet-Biedl syndrome Diseases 0.000 claims description 2
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 2
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 2
206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 claims description 2
108090000095 Neurotrophin-6 Proteins 0.000 claims description 2
208000014769 Usher Syndromes Diseases 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
201000007790 vitelliform macular dystrophy Diseases 0.000 claims description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
102000014429 Insulin-like growth factor Human genes 0.000 claims 1
208000005587 Refsum Disease Diseases 0.000 claims 1
208000002474 Tinea Diseases 0.000 claims 1
241000893966 Trichophyton verrucosum Species 0.000 claims 1
229960003920 cocaine Drugs 0.000 claims 1
208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
210000001116 retinal neuron Anatomy 0.000 abstract description 9
206010038848 Retinal detachment Diseases 0.000 abstract description 3
208000036866 Vitreoretinopathy Diseases 0.000 abstract description 3
230000004438 eyesight Effects 0.000 abstract description 3
230000006785 proliferative vitreoretinopathy Effects 0.000 abstract description 3
230000004264 retinal detachment Effects 0.000 abstract description 3
230000000472 traumatic effect Effects 0.000 abstract description 2
208000007014 Retinitis pigmentosa Diseases 0.000 abstract 1
239000000047 product Substances 0.000 description 184
235000018102 proteins Nutrition 0.000 description 98
229920001223 polyethylene glycol Polymers 0.000 description 78
239000002202 Polyethylene glycol Substances 0.000 description 77
238000004113 cell culture Methods 0.000 description 65
229920000642 polymer Polymers 0.000 description 50
230000000694 effects Effects 0.000 description 39
125000000539 amino acid group Chemical group 0.000 description 29
210000001525 retina Anatomy 0.000 description 29
210000002569 neuron Anatomy 0.000 description 28
210000001508 eye Anatomy 0.000 description 24
238000006467 substitution reaction Methods 0.000 description 22
238000006243 chemical reaction Methods 0.000 description 21
210000002241 neurite Anatomy 0.000 description 21
241000699670 Mus sp. Species 0.000 description 20
235000001014 amino acid Nutrition 0.000 description 19
239000000126 substance Substances 0.000 description 19
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 18
239000000829 suppository Substances 0.000 description 18
238000009472 formulation Methods 0.000 description 17
238000002474 experimental method Methods 0.000 description 16
241000699666 Mus <mouse, genus> Species 0.000 description 15
229940024606 amino acid Drugs 0.000 description 15
150000001413 amino acids Chemical class 0.000 description 15
239000000872 buffer Substances 0.000 description 15
238000012217 deletion Methods 0.000 description 15
230000037430 deletion Effects 0.000 description 15
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
238000011161 development Methods 0.000 description 13
230000018109 developmental process Effects 0.000 description 13
239000002953 phosphate buffered saline Substances 0.000 description 13
241000700159 Rattus Species 0.000 description 12
125000003277 amino group Chemical group 0.000 description 11
230000035772 mutation Effects 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 11
239000000243 solution Substances 0.000 description 11
239000003981 vehicle Substances 0.000 description 11
230000027455 binding Effects 0.000 description 10
238000001212 derivatisation Methods 0.000 description 10
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
229940088679 drug related substance Drugs 0.000 description 10
229930195712 glutamate Natural products 0.000 description 10
230000008569 process Effects 0.000 description 10
239000013598 vector Substances 0.000 description 10
241000287828 Gallus gallus Species 0.000 description 9
101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 9
239000008186 active pharmaceutical agent Substances 0.000 description 9
235000013330 chicken meat Nutrition 0.000 description 9
230000006870 function Effects 0.000 description 9
230000014509 gene expression Effects 0.000 description 9
102000052654 human GDNF Human genes 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
208000017532 inherited retinal dystrophy Diseases 0.000 description 9
239000000790 retinal pigment Substances 0.000 description 9
230000002459 sustained effect Effects 0.000 description 9
NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 8
239000004472 Lysine Substances 0.000 description 8
102000004330 Rhodopsin Human genes 0.000 description 8
108090000820 Rhodopsin Proteins 0.000 description 8
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 8
-1 for example Proteins 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
239000002609 medium Substances 0.000 description 8
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
238000005932 reductive alkylation reaction Methods 0.000 description 8
230000008929 regeneration Effects 0.000 description 8
238000011069 regeneration method Methods 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
201000004569 Blindness Diseases 0.000 description 7
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
241000283973 Oryctolagus cuniculus Species 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
238000005917 acylation reaction Methods 0.000 description 7
125000003172 aldehyde group Chemical group 0.000 description 7
229960002685 biotin Drugs 0.000 description 7
235000020958 biotin Nutrition 0.000 description 7
239000011616 biotin Substances 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
230000001575 pathological effect Effects 0.000 description 7
230000035515 penetration Effects 0.000 description 7
239000000049 pigment Substances 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
230000001228 trophic effect Effects 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 6
238000005804 alkylation reaction Methods 0.000 description 6
210000005252 bulbus oculi Anatomy 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 6
238000011534 incubation Methods 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
239000010410 layer Substances 0.000 description 6
239000000463 material Substances 0.000 description 6
239000012528 membrane Substances 0.000 description 6
210000004379 membrane Anatomy 0.000 description 6
238000002703 mutagenesis Methods 0.000 description 6
231100000350 mutagenesis Toxicity 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
230000016732 phototransduction Effects 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
210000004129 prosencephalon Anatomy 0.000 description 6
210000000844 retinal pigment epithelial cell Anatomy 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
241000894007 species Species 0.000 description 6
230000004393 visual impairment Effects 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
241000282412 Homo Species 0.000 description 5
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 5
201000007737 Retinal degeneration Diseases 0.000 description 5
208000032430 Retinal dystrophy Diseases 0.000 description 5
230000010933 acylation Effects 0.000 description 5
230000029936 alkylation Effects 0.000 description 5
210000002932 cholinergic neuron Anatomy 0.000 description 5
238000010494 dissociation reaction Methods 0.000 description 5
230000005593 dissociations Effects 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
238000001415 gene therapy Methods 0.000 description 5
230000034659 glycolysis Effects 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
239000002502 liposome Substances 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
230000000877 morphologic effect Effects 0.000 description 5
230000000508 neurotrophic effect Effects 0.000 description 5
238000007911 parenteral administration Methods 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
230000008092 positive effect Effects 0.000 description 5
230000002035 prolonged effect Effects 0.000 description 5
230000004258 retinal degeneration Effects 0.000 description 5
230000000007 visual effect Effects 0.000 description 5
108020004414 DNA Proteins 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
239000012981 Hank's balanced salt solution Substances 0.000 description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
229930040373 Paraformaldehyde Natural products 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
102000043168 TGF-beta family Human genes 0.000 description 4
108091085018 TGF-beta family Proteins 0.000 description 4
230000009471 action Effects 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
238000002659 cell therapy Methods 0.000 description 4
230000008859 change Effects 0.000 description 4
239000003638 chemical reducing agent Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
229920001577 copolymer Polymers 0.000 description 4
230000034994 death Effects 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
230000000984 immunochemical effect Effects 0.000 description 4
238000002372 labelling Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
239000011859 microparticle Substances 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
210000002161 motor neuron Anatomy 0.000 description 4
230000014511 neuron projection development Effects 0.000 description 4
230000003204 osmotic effect Effects 0.000 description 4
229920002866 paraformaldehyde Polymers 0.000 description 4
230000007170 pathology Effects 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 4
210000000278 spinal cord Anatomy 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
239000000758 substrate Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
241000283707 Capra Species 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
101800003838 Epidermal growth factor Proteins 0.000 description 3
102400001368 Epidermal growth factor Human genes 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000032578 Inherited retinal disease Diseases 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
108010058846 Ovalbumin Proteins 0.000 description 3
108090000526 Papain Proteins 0.000 description 3
208000018737 Parkinson disease Diseases 0.000 description 3
229920000954 Polyglycolide Polymers 0.000 description 3
239000004372 Polyvinyl alcohol Substances 0.000 description 3
239000004365 Protease Substances 0.000 description 3
206010057430 Retinal injury Diseases 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
229940054733 arestin Drugs 0.000 description 3
235000009582 asparagine Nutrition 0.000 description 3
229960001230 asparagine Drugs 0.000 description 3
238000003556 assay Methods 0.000 description 3
210000003050 axon Anatomy 0.000 description 3
230000003376 axonal effect Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
230000030833 cell death Effects 0.000 description 3
230000011748 cell maturation Effects 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
210000001175 cerebrospinal fluid Anatomy 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
210000000795 conjunctiva Anatomy 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
238000009826 distribution Methods 0.000 description 3
210000005064 dopaminergic neuron Anatomy 0.000 description 3
230000003291 dopaminomimetic effect Effects 0.000 description 3
210000002257 embryonic structure Anatomy 0.000 description 3
238000005538 encapsulation Methods 0.000 description 3
229940116977 epidermal growth factor Drugs 0.000 description 3
201000006321 fundus dystrophy Diseases 0.000 description 3
239000000499 gel Substances 0.000 description 3
235000013922 glutamic acid Nutrition 0.000 description 3
239000004220 glutamic acid Substances 0.000 description 3
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
238000002955 isolation Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
229940126601 medicinal product Drugs 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
230000007514 neuronal growth Effects 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
229940092253 ovalbumin Drugs 0.000 description 3
229940055729 papain Drugs 0.000 description 3
235000019834 papain Nutrition 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
238000002135 phase contrast microscopy Methods 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920000747 poly(lactic acid) Polymers 0.000 description 3
229920002451 polyvinyl alcohol Polymers 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
238000011552 rat model Methods 0.000 description 3
238000010188 recombinant method Methods 0.000 description 3
210000003583 retinal pigment epithelium Anatomy 0.000 description 3
239000002356 single layer Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
230000032258 transport Effects 0.000 description 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
206010003694 Atrophy Diseases 0.000 description 2
239000012583 B-27 Supplement Substances 0.000 description 2
101001011741 Bos taurus Insulin Proteins 0.000 description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
102000016911 Deoxyribonucleases Human genes 0.000 description 2
108010053770 Deoxyribonucleases Proteins 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
239000005700 Putrescine Substances 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
102000004338 Transferrin Human genes 0.000 description 2
108090000901 Transferrin Proteins 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000003732 agents acting on the eye Substances 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
108010068380 arginylarginine Proteins 0.000 description 2
210000001130 astrocyte Anatomy 0.000 description 2
230000037444 atrophy Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000008033 biological extinction Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000005056 cell body Anatomy 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
230000005779 cell damage Effects 0.000 description 2
208000037887 cell injury Diseases 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000008139 complexing agent Substances 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
125000002228 disulfide group Chemical group 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
210000000744 eyelid Anatomy 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
208000005017 glioblastoma Diseases 0.000 description 2
239000008103 glucose Substances 0.000 description 2
108010015792 glycyllysine Proteins 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
230000028993 immune response Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
GLMUAFMGXXHGLU-VQAITOIOSA-N minocycline hydrochloride Chemical compound [H+].[Cl-].C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O GLMUAFMGXXHGLU-VQAITOIOSA-N 0.000 description 2
239000003607 modifier Substances 0.000 description 2
229940126619 mouse monoclonal antibody Drugs 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
230000000626 neurodegenerative effect Effects 0.000 description 2
239000002581 neurotoxin Substances 0.000 description 2
231100000618 neurotoxin Toxicity 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
229940023490 ophthalmic product Drugs 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000008832 photodamage Effects 0.000 description 2
239000004633 polyglycolic acid Substances 0.000 description 2
239000004626 polylactic acid Substances 0.000 description 2
108010055896 polyornithine Proteins 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000013589 supplement Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
239000012581 transferrin Substances 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical group CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
HJFCVJKLGPYQDB-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine Chemical compound C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 HJFCVJKLGPYQDB-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
206010053227 AIDS retinopathy Diseases 0.000 description 1
241000220479 Acacia Species 0.000 description 1
208000032484 Accidental exposure to product Diseases 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
102000057234 Acyl transferases Human genes 0.000 description 1
108700016155 Acyl transferases Proteins 0.000 description 1
YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 1
WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
JSLGXODUIAFWCF-WDSKDSINSA-N Arg-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O JSLGXODUIAFWCF-WDSKDSINSA-N 0.000 description 1
QAODJPUKWNNNRP-DCAQKATOSA-N Arg-Glu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QAODJPUKWNNNRP-DCAQKATOSA-N 0.000 description 1
PPPXVIBMLFWNSK-BQBZGAKWSA-N Arg-Gly-Cys Chemical compound C(C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N PPPXVIBMLFWNSK-BQBZGAKWSA-N 0.000 description 1
BFDDUDQCPJWQRQ-IHRRRGAJSA-N Arg-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O BFDDUDQCPJWQRQ-IHRRRGAJSA-N 0.000 description 1
VPSHHQXIWLGVDD-ZLUOBGJFSA-N Asp-Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VPSHHQXIWLGVDD-ZLUOBGJFSA-N 0.000 description 1
FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
101100222854 Bacillus subtilis (strain 168) czcO gene Proteins 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
101001086405 Bos taurus Rhodopsin Proteins 0.000 description 1
238000006418 Brown reaction Methods 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
QJUDRFBUWAGUSG-SRVKXCTJSA-N Cys-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N QJUDRFBUWAGUSG-SRVKXCTJSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
239000001116 FEMA 4028 Substances 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
DTLLNDVORUEOTM-WDCWCFNPSA-N Glu-Thr-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DTLLNDVORUEOTM-WDCWCFNPSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
KAXZXLSXFWSNNZ-XVYDVKMFSA-N His-Ser-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KAXZXLSXFWSNNZ-XVYDVKMFSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
DPTBVFUDCPINIP-JURCDPSOSA-N Ile-Ala-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DPTBVFUDCPINIP-JURCDPSOSA-N 0.000 description 1
CMNMPCTVCWWYHY-MXAVVETBSA-N Ile-His-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)O)N CMNMPCTVCWWYHY-MXAVVETBSA-N 0.000 description 1
BCVIOZZGJNOEQS-XKNYDFJKSA-N Ile-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)[C@@H](C)CC BCVIOZZGJNOEQS-XKNYDFJKSA-N 0.000 description 1
WMDZARSFSMZOQO-DRZSPHRISA-N Ile-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 WMDZARSFSMZOQO-DRZSPHRISA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
102100025947 Insulin-like growth factor II Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
229930195714 L-glutamate Natural products 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000880493 Leptailurus serval Species 0.000 description 1
YOZCKMXHBYKOMQ-IHRRRGAJSA-N Leu-Arg-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOZCKMXHBYKOMQ-IHRRRGAJSA-N 0.000 description 1
UCDHVOALNXENLC-KBPBESRZSA-N Leu-Gly-Tyr Chemical compound CC(C)C[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 UCDHVOALNXENLC-KBPBESRZSA-N 0.000 description 1
ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
ZTPWXNOOKAXPPE-DCAQKATOSA-N Lys-Arg-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N ZTPWXNOOKAXPPE-DCAQKATOSA-N 0.000 description 1
GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
ZXFRGTAIIZHNHG-AJNGGQMLSA-N Lys-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N ZXFRGTAIIZHNHG-AJNGGQMLSA-N 0.000 description 1
NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
206010025412 Macular dystrophy congenital Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101100537961 Methanosarcina mazei (strain ATCC BAA-159 / DSM 3647 / Goe1 / Go1 / JCM 11833 / OCM 88) trkA2 gene Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
JMCOUWKXLXDERB-WMZOPIPTSA-N Phe-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 JMCOUWKXLXDERB-WMZOPIPTSA-N 0.000 description 1
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001756 Polyvinyl chloride acetate Polymers 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
101100068253 Rattus norvegicus Gdnf gene Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
102000005801 Rod Opsins Human genes 0.000 description 1
108010005063 Rod Opsins Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 1
BYIROAKULFFTEK-CIUDSAMLSA-N Ser-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO BYIROAKULFFTEK-CIUDSAMLSA-N 0.000 description 1
KNCJWSPMTFFJII-ZLUOBGJFSA-N Ser-Cys-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O KNCJWSPMTFFJII-ZLUOBGJFSA-N 0.000 description 1
XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
241000906446 Theraps Species 0.000 description 1
NLSNVZAREYQMGR-HJGDQZAQSA-N Thr-Asp-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NLSNVZAREYQMGR-HJGDQZAQSA-N 0.000 description 1
COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
BZTSQFWJNJYZSX-JRQIVUDYSA-N Thr-Tyr-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O BZTSQFWJNJYZSX-JRQIVUDYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102100038313 Transcription factor E2-alpha Human genes 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
WPXKRJVHBXYLDT-JUKXBJQTSA-N Tyr-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N WPXKRJVHBXYLDT-JUKXBJQTSA-N 0.000 description 1
RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 1
OTJMMKPMLUNTQT-AVGNSLFASA-N Val-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N OTJMMKPMLUNTQT-AVGNSLFASA-N 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
231100000818 accidental exposure Toxicity 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
108010087924 alanylproline Proteins 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229910001508 alkali metal halide Inorganic materials 0.000 description 1
150000008045 alkali metal halides Chemical class 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
108010092854 aspartyllysine Proteins 0.000 description 1
239000002585 base Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
235000011175 beta-cyclodextrine Nutrition 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000037237 body shape Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
108010046910 brain-derived growth factor Proteins 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001720 carbohydrates Chemical group 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229940105657 catalase Drugs 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000003837 chick embryo Anatomy 0.000 description 1
229960003260 chlorhexidine Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229940107161 cholesterol Drugs 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
208000003571 choroideremia Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
210000004081 cilia Anatomy 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000010367 cloning Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
230000004456 color vision Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000013267 controlled drug release Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
108010016616 cysteinylglycine Proteins 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
235000014103 egg white Nutrition 0.000 description 1
210000000969 egg white Anatomy 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000005891 glutamate uptake involved in synaptic transmission Effects 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
150000002334 glycols Chemical group 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
230000010005 growth-factor like effect Effects 0.000 description 1
230000012447 hatching Effects 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
210000002287 horizontal cell Anatomy 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
108010051673 leucyl-glycyl-phenylalanine Proteins 0.000 description 1
108010034529 leucyl-lysine Proteins 0.000 description 1
239000003446 ligand Substances 0.000 description 1
208000018769 loss of vision Diseases 0.000 description 1
231100000864 loss of vision Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
108010054155 lysyllysine Proteins 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
150000002689 maleic acids Chemical class 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
238000007491 morphometric analysis Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003078 multipolar neuron Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
230000006576 neuronal survival Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
230000008823 permeabilization Effects 0.000 description 1
108010073101 phenylalanylleucine Proteins 0.000 description 1
108010083476 phenylalanyltryptophan Proteins 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
230000004310 photopic vision Effects 0.000 description 1
229960001416 pilocarpine Drugs 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
108010054442 polyalanine Proteins 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
210000003994 retinal ganglion cell Anatomy 0.000 description 1
229960000342 retinol acetate Drugs 0.000 description 1
235000019173 retinyl acetate Nutrition 0.000 description 1
239000011770 retinyl acetate Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000002508 rod bipolar cell Anatomy 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
210000004116 schwann cell Anatomy 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
229940091258 selenium supplement Drugs 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
229960001471 sodium selenite Drugs 0.000 description 1
239000011781 sodium selenite Substances 0.000 description 1
235000015921 sodium selenite Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000009331 sowing Methods 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
150000003464 sulfur compounds Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229940042585 tocopherol acetate Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
102000015533 trkA Receptor Human genes 0.000 description 1
108010064884 trkA Receptor Proteins 0.000 description 1
101150025395 trkA gene Proteins 0.000 description 1
101150113435 trkA1 gene Proteins 0.000 description 1
102000015534 trkB Receptor Human genes 0.000 description 1
108010064880 trkB Receptor Proteins 0.000 description 1
102000047459 trkC Receptor Human genes 0.000 description 1
108010064892 trkC Receptor Proteins 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960004224 tyloxapol Drugs 0.000 description 1
229920001664 tyloxapol Polymers 0.000 description 1
MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000003242 unipolar neuron Anatomy 0.000 description 1
210000003934 vacuole Anatomy 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
210000000857 visual cortex Anatomy 0.000 description 1
230000004382 visual function Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Non-Volatile Memory (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SK659-98A 1995-11-29 1996-11-22 Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product SK65998A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/564,833 US5641750A (en)	1995-11-29	1995-11-29	Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
PCT/US1996/018806 WO1997019694A1 (en)	1995-11-29	1996-11-22	Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product

Publications (1)

Publication Number	Publication Date
SK65998A3 true SK65998A3 (en)	1999-09-10

Family

ID=24256084

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK659-98A SK65998A3 (en)	1995-11-29	1996-11-22	Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product

Country Status (20)

Country	Link
US (2)	US5641750A (de)
EP (1)	EP0863766B1 (de)
JP (1)	JP2000502057A (de)
KR (1)	KR19990071540A (de)
CN (1)	CN1203532A (de)
AT (1)	ATE194773T1 (de)
AU (1)	AU698062B2 (de)
BR (1)	BR9611750A (de)
CZ (1)	CZ154498A3 (de)
DE (1)	DE69609422T2 (de)
DK (1)	DK0863766T3 (de)
ES (1)	ES2149511T3 (de)
GR (1)	GR3034393T3 (de)
HU (1)	HUP9802374A2 (de)
IL (1)	IL124601A0 (de)
MX (1)	MX9803993A (de)
NO (1)	NO982275L (de)
PT (1)	PT863766E (de)
SK (1)	SK65998A3 (de)
WO (1)	WO1997019694A1 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020064870A1 (en) *	1993-03-03	2002-05-30	Pascale Briand	Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases
FR2704556B1 (fr)	1993-04-30	1995-07-13	Rhone Poulenc Rorer Sa	Virus recombinants et leur utilisation en thérapie génique.
US8431119B2 (en) *	1993-10-04	2013-04-30	Aventis Pharma S.A.	Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
FR2710846B1 (fr)	1993-10-04	1995-12-22	Rhone Poulenc Rorer Sa	Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives.
US7109308B1 (en)	1994-03-08	2006-09-19	Human Genome Sciences, Inc.	Antibodies to human vascular endothelial growth factor 2
US7186688B1 (en)	1994-03-08	2007-03-06	Human Genome Sciences, Inc.	Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7153827B1 (en)	1994-03-08	2006-12-26	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 and methods of use
US6040157A (en)	1994-03-08	2000-03-21	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
EP0751992B1 (de)	1994-03-08	2005-11-09	Human Genome Sciences, Inc.	Vaskularer endothelialer wachstumsfaktor 2
US6184200B1 (en) *	1995-09-28	2001-02-06	Amgen Inc.	Truncated glial cell line-derived neurotrophic factor
US5731284A (en) *	1995-09-28	1998-03-24	Amgen Inc.	Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5641750A (en) *	1995-11-29	1997-06-24	Amgen Inc.	Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US6878544B2 (en) *	1996-04-19	2005-04-12	Neurotech Sa	Retinal cell lines with extended life-span and their applications
US6677135B1 (en)	1996-05-08	2004-01-13	Biogen, Inc.	Ret ligand (RetL) for stimulating neutral and renal growth
KR100514277B1 (ko)	1996-09-13	2005-09-13	유겐가이샤 사이센딴이가꾸겡꾸쇼	신경 영양 인자의 안과용 조성물, 시신경 기능 장애 치료제 및 시신경 기능 장애 치료 방법
CA2275141A1 (en) *	1996-10-29	1998-05-07	Thomas Spies	Cell stress regulated human mhc class i gene
NZ501423A (en) *	1997-04-17	2002-02-01	Univ Washington	Receptors for TGF-beta-related neurotrophic factors and use for treating disease
US20030121064A1 (en) *	1997-06-11	2003-06-26	Ann Logan	CNS neuroregenerative compositions and methods of use
CA2301693A1 (en) *	1997-09-19	1999-04-01	Klaus Unsicker	Cytokines having neurotrophic activity
US7338976B1 (en)	1998-08-14	2008-03-04	Gpi Nil Holdings, Inc.	Heterocyclic esters or amides for vision and memory disorders
US6335348B1 (en)	1998-08-14	2002-01-01	Gpi Nil Holdings, Inc.	Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6333340B1 (en)	1998-08-14	2001-12-25	Gpi Nil Holdings, Inc.	Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en)	1998-08-14	2002-01-15	Gpi Nil Holdings, Inc.	N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6218423B1 (en)	1998-08-14	2001-04-17	Gpi Nil Holdings, Inc.	Pyrrolidine derivatives for vision and memory disorders
US6506788B1 (en)	1998-08-14	2003-01-14	Gpi Nil Holdings, Inc.	N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6384056B1 (en)	1998-08-14	2002-05-07	Gpi Nil Holdings, Inc.	Heterocyclic thioesters or ketones for vision and memory disorders
US7265150B1 (en)	1998-08-14	2007-09-04	Gpi Nil Holdings Inc.	Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6399648B1 (en)	1998-08-14	2002-06-04	Gpi Nil Holdings, Inc.	N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US7410995B1 (en)	1998-08-14	2008-08-12	Gpi Nil Holdings Inc.	N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US6376517B1 (en)	1998-08-14	2002-04-23	Gpi Nil Holdings, Inc.	Pipecolic acid derivatives for vision and memory disorders
US6337340B1 (en)	1998-08-14	2002-01-08	Gpi Nil Holdings, Inc.	Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
FR2784898A1 (fr) *	1998-10-26	2000-04-28	Univ Pasteur	Utilisation du gdnf pour le traitement de la degenerescence retinienne
TWI246421B (en) *	1998-12-03	2006-01-01	Alcon Mfg Ltd	Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
US6906077B1 (en) *	1998-12-03	2005-06-14	Alcon Manufacturing, Ltd.	Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
IT1305294B1 (it)	1999-01-29	2001-05-04	Alessandro Lambiase	Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
US7223724B1 (en)	1999-02-08	2007-05-29	Human Genome Sciences, Inc.	Use of vascular endothelial growth factor to treat photoreceptor cells
WO2000045835A1 (en) *	1999-02-08	2000-08-10	Human Genome Sciences, Inc.	Vascular endothelial growth factor-2
US6361771B1 (en) *	1999-04-06	2002-03-26	Neurotech S.A.	ARPE-19 as a platform cell line for encapsulated cell-based delivery
US20070071734A1 (en) *	1999-04-06	2007-03-29	Weng Tao	ARPE-19 as platform cell line for encapsulated cell-based delivery
EP1279406A4 (de)	2000-04-03	2007-10-24	Santen Pharmaceutical Co Ltd	Transporters und arzneimittelabgabesysteme die diese verwenden
US6864243B1 (en)	2000-05-12	2005-03-08	Inspire Pharmaceuticals, Inc.	Method for treating retinal degeneration with purinergic receptor agonists
US7273751B2 (en)	2000-08-04	2007-09-25	Human Genome Science, Inc.	Vascular endothelial growth factor-2
HUP0300727A3 (en) *	2000-08-08	2005-12-28	M G V S Ltd Nazareth Illit	Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis
CA2707827A1 (en)	2001-04-11	2002-10-24	Senju Pharmaceutical Co., Ltd.	Visual function disorder improving agents containing rho kinase inhibitors
DE60236646D1 (de)	2001-04-13	2010-07-22	Human Genome Sciences Inc	Anti-VEGF-2 Antikörper
US7402312B2 (en)	2001-04-13	2008-07-22	Human Genome Sciences, Inc.	Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20040254197A1 (en) *	2001-09-28	2004-12-16	Santen Pharmaceutical Co., Ltd.	Injections for eye tissues containing drug bonded to polyethlene glycol
WO2003047525A2 (en) *	2001-12-03	2003-06-12	The Regents Of The University Of California	Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
EP1463530A4 (de) *	2001-12-19	2006-09-06	Lijun Wang	Adeno-assoziierte virusvermittelte abgabe von gdnf an skelettmuskeln
AU2003209297A1 (en) *	2002-01-18	2003-09-02	Massachusetts Eye And Ear Infirmary	Methods and compositions for preserving the viability of photoreceptor cells
WO2004007749A2 (en) *	2002-07-12	2004-01-22	University Of Washington	Methods and systems for extended in vitro culture of neuronal cells
CA2689424A1 (en) *	2002-09-29	2004-04-08	Surmodics, Inc.	Methods for treatment and/or prevention of retinal disease
US8518390B2 (en)	2003-06-27	2013-08-27	Advanced Technologies And Regenerative Medicine, Llc	Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US8491883B2 (en) *	2003-06-27	2013-07-23	Advanced Technologies And Regenerative Medicine, Llc	Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US9572840B2 (en)	2003-06-27	2017-02-21	DePuy Synthes Products, Inc.	Regeneration and repair of neural tissue using postpartum-derived cells
ES2564044T3 (es)	2003-06-27	2016-03-17	DePuy Synthes Products, Inc.	Células posparto derivadas de tejido del cordón umbilical y métodos de preparación y uso de las mismas
US9592258B2 (en)	2003-06-27	2017-03-14	DePuy Synthes Products, Inc.	Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8790637B2 (en) *	2003-06-27	2014-07-29	DePuy Synthes Products, LLC	Repair and regeneration of ocular tissue using postpartum-derived cells
US7875272B2 (en)	2003-06-27	2011-01-25	Ethicon, Incorporated	Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
AU2005322060B2 (en)	2003-06-27	2011-11-17	Ethicon Incorporated	Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
GB0328021D0 (en)	2003-12-03	2004-01-07	Inst Of Ophthalmology	Method
US20060171930A1 (en) *	2004-12-21	2006-08-03	Agnieszka Seyda	Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
US20060153815A1 (en) *	2004-12-21	2006-07-13	Agnieszka Seyda	Tissue engineering devices for the repair and regeneration of tissue
WO2006083394A2 (en) *	2004-12-21	2006-08-10	Ethicon, Inc.	Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
WO2006071802A2 (en)	2004-12-23	2006-07-06	Ethicon Incorporated	Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
RU2284812C1 (ru) *	2005-02-15	2006-10-10	Уфимский научно-исследовательский институт глазных болезней	Способ лечения пролиферативной витреоретинопатии
US8309057B2 (en) *	2005-06-10	2012-11-13	The Invention Science Fund I, Llc	Methods for elevating neurotrophic agents
US8409263B2 (en) *	2005-08-05	2013-04-02	Gholam A. Peyman	Methods to regulate polarization of excitable cells
US7592330B2 (en) *	2005-08-08	2009-09-22	Massachusetts Eye And Ear Infirmary	Methods and compositions for preserving the viability of photoreceptor cells
ITRM20050447A1 (it) *	2005-08-19	2007-02-20	Anabasis S R L	Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
CN101374946B (zh) *	2005-12-16	2017-07-18	伊西康公司	用于在组织相容性不匹配的移植中抑制有害的免疫反应的组合物和方法
US9125906B2 (en)	2005-12-28	2015-09-08	DePuy Synthes Products, Inc.	Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
SG170789A1 (en) *	2005-12-28	2011-05-30	Ethicon Inc	Treatment of peripheral vascular disease using postpartum-derived cells
US20080145405A1 (en) *	2006-12-15	2008-06-19	Kunzler Jay F	Drug delivery devices
WO2008131368A2 (en)	2007-04-20	2008-10-30	Acucela Inc.	Styrenyl derivative compounds for treating ophthalmic diseases and disorders
CN103664637B (zh)	2007-06-29	2016-02-03	奥克塞拉有限公司	用于治疗眼科疾病和紊乱的炔基苯基衍生化合物
TW200922548A (en)	2007-10-05	2009-06-01	Acucela Inc	Alkoxy compounds for disease treatment
US8034329B2 (en) *	2007-10-05	2011-10-11	Advanced Technologies And Regenerative Medicine, Llc	Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
US8461389B2 (en)	2008-04-18	2013-06-11	University College Dublin, National University Of Ireland, Dublin	Psycho-pharmaceuticals
PT2379087E (pt) *	2008-12-19	2014-12-02	Depuy Synthes Products Llc	Células derivadas do tecido do cordão umbilical para o tratamento da dor neuropática e espasticidade
BRPI0923068B1 (pt)	2008-12-19	2021-05-25	Advanced Technologies And Regenerative Medicine, Llc	Uso de células derivadas de tecido de cordão umbilical para tratar um paciente tendo uma doença, distúrbio ou injúria pulmonar
WO2010071863A1 (en) *	2008-12-19	2010-06-24	Ethicon, Incorporated	Regeneration and repair of neural tissue following injury
US10179900B2 (en) *	2008-12-19	2019-01-15	DePuy Synthes Products, Inc.	Conditioned media and methods of making a conditioned media
CN102498204B (zh) *	2009-03-26	2015-02-04	德普伊新特斯产品有限责任公司	人脐带组织细胞作为用于阿尔茨海默病的疗法
JP6301263B2 (ja)	2011-12-23	2018-03-28	デピュイ・シンセス・プロダクツ・インコーポレイテッド	ヒト臍帯組織由来細胞の検出
HK1210969A1 (en)	2012-01-20	2016-05-13	奥克塞拉有限公司	Substituted heterocyclic compounds for disease treatment
JP2016512528A (ja)	2013-03-12	2016-04-28	アクセラインコーポレイテッド	眼疾患及び眼障害を治療するための置換された３−フェニルプロピルアミン誘導体
WO2014152511A1 (en)	2013-03-15	2014-09-25	The Jackson Laboratory	Methods for promoting wound healing and hair growth
US10883108B2 (en)	2016-03-31	2021-01-05	The Schepens Eye Research Institute, Inc.	Endomucin inhibitor as an anti-angiogenic agent
US11912750B2 (en)	2016-11-10	2024-02-27	Keros Therapeutics, Inc.	GDNF fusion polypeptides and methods of use thereof
EP4520828A3 (de)	2016-11-15	2025-07-09	The Schepens Eye Research Institute, Inc.	Zusammensetzungen und verfahren zur behandlung von aberranter angiogenese
WO2019070917A1 (en)	2017-10-03	2019-04-11	The Schepens Eye Research Institute, Inc.	COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
WO2019099560A1 (en)	2017-11-14	2019-05-23	The Schepens Eye Research Institute, Inc.	Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
CN113759131B (zh) *	2021-09-28	2024-10-29	嘉兴蔚康科技有限公司	一种靶标蛋白组合在检测视网膜黄斑病变中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3981303A (en) *	1971-09-09	1976-09-21	Alza Corporation	Bioerodible ocular device
US3986510A (en) *	1971-09-09	1976-10-19	Alza Corporation	Bioerodible ocular device
US3995635A (en) *	1971-09-09	1976-12-07	Alza Corporation	Ocular insert
US4188373A (en) *	1976-02-26	1980-02-12	Cooper Laboratories, Inc.	Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4217898A (en) *	1978-10-23	1980-08-19	Alza Corporation	System with microporous reservoir having surface for diffusional delivery of agent
US4474452A (en) *	1981-05-13	1984-10-02	Pitney Bowes Inc.	Safety device for cam yoke used in electrophotocopier reciprocating carriage
US4518584A (en) *	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
US4474751A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Ophthalmic drug delivery system utilizing thermosetting gels
US4474752A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Drug delivery system utilizing thermosetting gels
EP0154316B1 (de) *	1984-03-06	1989-09-13	Takeda Chemical Industries, Ltd.	Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
US4863457A (en) *	1986-11-24	1989-09-05	Lee David A	Drug delivery device
US5158881A (en) *	1987-11-17	1992-10-27	Brown University Research Foundation	Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) *	1987-11-17	1990-01-09	Brown University Research Foundation	In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) *	1987-11-17	1992-04-21	Brown University Research Foundation	Neurological therapy devices
US4853224A (en) *	1987-12-22	1989-08-01	Visionex	Biodegradable ocular implants
US4865846A (en) *	1988-06-03	1989-09-12	Kaufman Herbert E	Drug delivery system
US4882150A (en) *	1988-06-03	1989-11-21	Kaufman Herbert E	Drug delivery system
US5011472A (en) *	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
WO1990006952A1 (fr) *	1988-12-22	1990-06-28	Kirin-Amgen, Inc.	Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5221696A (en) *	1989-03-29	1993-06-22	Alcon Laboratories, Inc.	Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
DK0423980T3 (da) *	1989-10-16	2000-10-09	Amgen Inc	Stamcellefaktor
WO1991010470A1 (en) *	1990-01-08	1991-07-25	Brown University Research Foundation	Devices and methods for enhanced delivery of active factors
US5252714A (en) *	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
WO1993006116A1 (en) *	1991-09-20	1993-04-01	Syntex-Synergen Neuroscience Joint Venture	Glial derived neurotrophic factor
US5470582A (en) *	1992-02-07	1995-11-28	Syntex (U.S.A.) Inc.	Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
CA2130115C (en) *	1992-02-14	2004-09-14	Matthew M. Lavail	Prevention of retinal injury and degeneration by specific factors
US5384333A (en) *	1992-03-17	1995-01-24	University Of Miami	Biodegradable injectable drug delivery polymer
WO1993021902A1 (en) *	1992-04-24	1993-11-11	Somatix Therapy Corporation	Biocompatible, therapeutic, implantable device
WO1995017203A1 (en) *	1993-12-22	1995-06-29	The University Of Medicine And Dentistry Of New Jersey	Novel nucleic acid sequences isolated from glial cells
US5422116A (en) *	1994-02-18	1995-06-06	Ciba-Geigy Corporation	Liquid ophthalmic sustained release delivery system
US5733875A (en) *	1994-11-15	1998-03-31	Amgen Inc.	Methods of using GDNF as a neuroprotective agent
US5641749A (en) *	1995-11-29	1997-06-24	Amgen Inc.	Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) *	1995-11-29	1997-06-24	Amgen Inc.	Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product

1995
- 1995-11-29 US US08/564,833 patent/US5641750A/en not_active Expired - Lifetime
1996
- 1996-11-22 EP EP96941452A patent/EP0863766B1/de not_active Expired - Lifetime
- 1996-11-22 HU HU9802374A patent/HUP9802374A2/hu unknown
- 1996-11-22 CZ CZ981544A patent/CZ154498A3/cs unknown
- 1996-11-22 SK SK659-98A patent/SK65998A3/sk unknown
- 1996-11-22 PT PT96941452T patent/PT863766E/pt unknown
- 1996-11-22 DE DE69609422T patent/DE69609422T2/de not_active Expired - Lifetime
- 1996-11-22 WO PCT/US1996/018806 patent/WO1997019694A1/en not_active Ceased
- 1996-11-22 IL IL12460196A patent/IL124601A0/xx unknown
- 1996-11-22 BR BR9611750A patent/BR9611750A/pt not_active Application Discontinuation
- 1996-11-22 CN CN96198646A patent/CN1203532A/zh active Pending
- 1996-11-22 JP JP9520575A patent/JP2000502057A/ja active Pending
- 1996-11-22 AU AU10592/97A patent/AU698062B2/en not_active Ceased
- 1996-11-22 KR KR1019980703814A patent/KR19990071540A/ko not_active Ceased
- 1996-11-22 AT AT96941452T patent/ATE194773T1/de active
- 1996-11-22 ES ES96941452T patent/ES2149511T3/es not_active Expired - Lifetime
- 1996-11-22 DK DK96941452T patent/DK0863766T3/da active
1997
- 1997-02-06 US US08/795,628 patent/US5736516A/en not_active Expired - Lifetime
1998
- 1998-05-19 NO NO982275A patent/NO982275L/no unknown
- 1998-05-20 MX MX9803993A patent/MX9803993A/es unknown
2000
- 2000-09-13 GR GR20000402083T patent/GR3034393T3/el unknown

Also Published As

Publication number	Publication date
NO982275D0 (no)	1998-05-19
JP2000502057A (ja)	2000-02-22
GR3034393T3 (en)	2000-12-29
WO1997019694A1 (en)	1997-06-05
DE69609422T2 (de)	2001-02-15
US5641750A (en)	1997-06-24
PT863766E (pt)	2000-11-30
US5736516A (en)	1998-04-07
EP0863766B1 (de)	2000-07-19
CN1203532A (zh)	1998-12-30
BR9611750A (pt)	1999-04-06
MX9803993A (es)	1998-09-30
AU1059297A (en)	1997-06-19
AU698062B2 (en)	1998-10-22
NO982275L (no)	1998-07-29
ATE194773T1 (de)	2000-08-15
DK0863766T3 (da)	2000-10-23
EP0863766A1 (de)	1998-09-16
KR19990071540A (ko)	1999-09-27
ES2149511T3 (es)	2000-11-01
HUP9802374A2 (hu)	1999-02-01
CZ154498A3 (cs)	1999-05-12
DE69609422D1 (de)	2000-08-24
IL124601A0 (en)	1998-12-06

Publication	Publication Date	Title
CZ154498A3 (cs)	1999-05-12	Použití proteinového produktu GDNF-faktoru k přípravě farmaceutických přípravků pro léčbu poškození nebo degenerace fotoreceptorů
JP4066201B2 (ja)	2008-03-26	膠細胞系由来神経栄養因子（ｇｄｎｆ）蛋白産生物を用いる網膜神経節細胞損傷の治療方法
US5929041A (en)	1999-07-27	Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US6043221A (en)	2000-03-28	Method for preventing and treating hearing loss using a neuturin protein product
US5837681A (en)	1998-11-17	Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
AU696772C (en)	1999-05-20	Method for treating retinal ganglion cell injury using glial cell line-derived neurotrophic factor (GDNF) protein product
CA2236157A1 (en)	1997-06-05	Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product
MXPA00000862A (en)	2001-05-07	Method for preventing and treating hearing loss using a neurturin protein product